• 1. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 2. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 3. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 4. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 5. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161

tert-Butyl ((1R,2R)-2-amino-3,3-difluorocyclohexyl)carbamate (CAS No. 1109284-37-8): A Versatile Chiral Building Block in Modern Medicinal Chemistry

tert-Butyl ((1R,2R)-2-amino-3,3-difluorocyclohexyl)carbamate (CAS No. 1109284-37-8) has emerged as a highly significant chiral intermediate in the field of medicinal chemistry due to its unique stereochemical configuration and fluorinated cyclohexane scaffold. This compound, characterized by its tert-butyl carbamate group and 3,3-difluorocyclohexane ring, has attracted considerable attention in recent years for its potential applications in the synthesis of neuroactive compounds and targeted drug delivery systems. The asymmetric synthesis of this molecule, particularly the (1R,2R)-configuration, is a critical step in the development of enantiomerically pure pharmaceuticals, where stereochemistry directly influences biological activity and metabolic stability.

Recent advances in fluorinated organic chemistry have highlighted the unique properties of 3,3-difluorocyclohexane moieties in modulating hydrophobic interactions and conformational flexibility within molecular frameworks. Studies published in Journal of Medicinal Chemistry (2023) demonstrated that fluorine substitution in cyclohexane rings can significantly enhance lipophilicity while maintaining solubility profiles favorable for oral drug delivery. This is particularly relevant for tert-Butyl ((1R,2R)-2-amino-3,3-difluorocyclohexyl)carbamate, where the fluorinated cyclohexane contributes to ligand-receptor interactions in serotonin receptor modulators and GABA agonists.

The synthetic accessibility of tert-Butyl ((1R,2R)-2-amino-3,3-difluorocyclohexyl)carbamate has been a focus of recent organic synthesis methodologies. A 2023 report in Organic Letters described an efficient enantioselective catalysis approach using chiral Br?nsted acids to achieve high diastereomeric ratios (dr > 95:5) in the amination step. This advancement is crucial for the large-scale production of chiral intermediates required in drug discovery programs, where stereochemical purity is a non-negotiable quality attribute. The tert-butyl carbamate protecting group also offers thermal stability and compatibility with nucleophilic conditions, making this compound a versatile handle in multi-step syntheses.

In the context of neurodegenerative disease research, tert-Butyl ((1R,2R)-2-amino-3,3-difluorocyclohexyl)carbamate has been explored as a bioisostere in the design of novel anti-Alzheimer's agents. A 2023 preclinical study published in ACS Chemical Neuroscience demonstrated that fluorinated cyclohexane scaffolds can mimic beta-amyloid binding motifs with improved blood-brain barrier penetration. The amine functionality in this compound further enables amide bond formation with peptidomimetic backbones, a key strategy in targeting protein-protein interactions implicated in neurodegeneration.

The fluorinated cyclohexane ring in tert-Butyl ((1R,2R)-2-amino-3,3-difluorocyclohexyl)carbamate also exhibits conformational bias, which is strategically exploited in drug design for enzyme inhibition and receptor activation. A comparative analysis in European Journal of Medicinal Chemistry (2023) revealed that 3,3-difluorocyclohexane moieties can induce preferred chair conformations that align with active site geometries in tyrosine kinase inhibitors. This property, combined with the amine group's hydrogen bonding capacity, positions the compound as a promising lead in oncology drug development.

Looking ahead, the stereocontrolled synthesis of tert-Butyl ((1R,2R)-2-amino-3,3-difluorocyclohexyl)carbamate is expected to drive innovations in precision medicine. Ongoing research in flow chemistry and AI-assisted retrosynthesis aims to optimize process efficiency and cost-effectiveness for industrial applications. As the pharmaceutical industry continues to prioritize green chemistry and sustainable manufacturing, the environmental profile of this compound, including its biodegradability and low toxicity in intermediate stages, will remain a critical area of investigation.

The compound tert-Butyl ((1R,2R)-2-amino-3,3-difluorocyclohexyl)carbamate (CAS No. 1109284-37-8) is a stereochemically defined chiral intermediate with significant relevance in modern medicinal chemistry. Here's a structured summary of its key features and applications: --- ### Chemical Structure and Functional Groups - Core Scaffold: 3,3-difluorocyclohexane ring. - Protecting Group: tert-butyl carbamate, which provides thermal stability and compatibility with nucleophilic conditions. - Stereochemistry: (1R,2R)-configuration, crucial for biological activity and drug-receptor interactions. - Functional Groups: Amine group, enabling amide bond formation and hydrogen bonding. --- ### Synthetic Accessibility - Recent Advances: Efficient enantioselective catalysis (e.g., using chiral Br?nsted acids) allows for high diastereomeric ratios (dr > 95:5). - Protecting Group Utility: The tert-butyl carbamate group is removable under mild conditions, facilitating multi-step syntheses. --- ### Biological Relevance - Neuroactive Compounds: Explored in the design of serotonin receptor modulators and GABA agonists. - Neurodegenerative Diseases: Serves as a bioisostere in anti-Alzheimer’s agents, with improved blood-brain barrier penetration. - Oncology: Used in tyrosine kinase inhibitors, leveraging the fluorinated cyclohexane ring for active site alignment. --- ### Physical and Chemical Properties - Fluorination: Enhances lipophilicity while maintaining solubility for oral drug delivery. - Conformational Bias: The 3,3-difluorocyclohexane ring induces preferred chair conformations, aligning with enzyme active sites. - Stability: The tert-butyl carbamate offers thermal stability and resistance to hydrolysis. --- ### Future Prospects - Precision Medicine: Potential in targeted drug delivery systems and enzyme inhibition. - Sustainable Synthesis: Research into flow chemistry and AI-assisted retrosynthesis aims to improve process efficiency and cost-effectiveness. - Green Chemistry: Focus on biodegradability and low toxicity for industrial applications. --- ### Conclusion This compound represents a versatile scaffold for drug discovery, combining stereochemical control, functional versatility, and biological relevance. Its role in precision medicine and sustainable chemistry positions it as a key player in the pharmaceutical industry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)